Research & Reconstitution Library

Tesamorelin BAC Water & Reconstitution Guide

Q: How much BAC water for 11.6 mg Tesamorelin?

For the FDA-approved EGRIFTA WR 11.6 mg/vial formulation, FDA labeling specifies 1.3 mL of bacteriostatic water.

Q: How do you calculate Tesamorelin concentration?

Concentration in mg/mL equals total Tesamorelin in mg divided by liquid volume in mL.

Q: Is Tesamorelin FDA approved?

FDA-licensed Tesamorelin formulations exist for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Tesamorelin is a synthetic growth hormone-releasing factor analog that has been studied extensively for reducing visceral adipose tissue in adults with HIV-associated lipodystrophy. The amount of diluent determines the resulting concentration, so there is no single universal BAC-water volume for every Tesamorelin vial or formulation.

FDA-licensed formulations Human clinical evidence GHRF analog Concentration mathematics

Scientific status reviewed September 10, 2026.

Scientific illustration

Conceptual illustration — not a molecular-structure rendering.

Tesamorelin Research Snapshot

Compound Tesamorelin

Compound class Growth hormone-releasing factor analog

Research category Metabolic / endocrine research

Regulatory status FDA-licensed formulations

Human evidence Multiple randomized trials

Documented formulations 2 mg/vial and 11.6 mg/vial

Current WR diluent Bacteriostatic Water for Injection

Current WR volume 1.3 mL for 11.6 mg vial

Last reviewed September 10, 2026

How Much BAC Water for Tesamorelin?

There is no single universal BAC-water amount for every Tesamorelin vial. The correct volume depends on the specific formulation and the target concentration. For the FDA-approved EGRIFTA WR 11.6 mg/vial formulation, the FDA labeling specifies 1.3 mL of bacteriostatic water, producing approximately 8.92 mg/mL.

Do not treat all Tesamorelin formulations as interchangeable.
EGRIFTA WR is an 11.6 mg/vial formulation using bacteriostatic water. EGRIFTA SV is a different 2 mg/vial formulation with different preparation requirements and uses Sterile Water for Injection rather than bacteriostatic water.

11.6 mg

EGRIFTA WR

The FDA-approved EGRIFTA WR formulation is supplied as 11.6 mg per vial. Its FDA labeling specifies bacteriostatic water as the supplied diluent and a 1.3 mL reconstitution volume.

Mathematical concentration: 11.6 mg ÷ 1.3 mL ≈ 8.92 mg/mL

FDA product-specific information

2 mg

EGRIFTA SV

EGRIFTA SV is a separate 2 mg/vial formulation. Its FDA labeling specifies Sterile Water for Injection as its diluent and a 0.5 mL reconstitution volume.

Mathematical concentration: 2 mg ÷ 0.5 mL = 4 mg/mL

Different formulation

Tesamorelin 11.6 mg Concentration Examples

The table below demonstrates the mathematics of concentration. Except for the clearly identified FDA product-specific formulation, these values are mathematical examples and should not be interpreted as recommended preparation instructions.

Vial quantity	0.5 mL	1 mL	1.3 mL	2 mL	2.5 mL	5 mL
11.6 mg Tesamorelin	23.20 mg/mL	11.60 mg/mL	8.92 mg/mL*	5.80 mg/mL	4.64 mg/mL	2.32 mg/mL

*8.92 mg/mL is the mathematical concentration corresponding to the FDA-labeled EGRIFTA WR 11.6 mg/vial formulation after reconstitution with 1.3 mL of its specified diluent.

Concentration mathematics

Mathematical concentration model. This illustration does not provide a universal preparation recommendation.

Need a different vial quantity or BAC-water volume?

Use the BacScience Universal BAC Water Calculator to calculate concentration from a custom vial quantity and liquid volume.

Open BAC Water Calculator

How Much BAC Water Should Be Added to an 11.6 mg Vial of Tesamorelin?

For the FDA-approved EGRIFTA WR 11.6 mg/vial formulation, the product labeling specifies 1.3 mL of bacteriostatic water. That is a formulation-specific instruction, not a universal Tesamorelin rule. Different Tesamorelin products, vial strengths, and research materials can have different formulation and reconstitution requirements.

Key distinction: The FDA-labeled EGRIFTA WR preparation produces approximately 8.92 mg/mL from 11.6 mg ÷ 1.3 mL. Changing the liquid volume changes the concentration mathematically; it does not change the total Tesamorelin quantity contained in the vial.

How much BAC water for Tesamorelin 11.6 mg?

The FDA labeling for EGRIFTA WR specifies 1.3 mL of bacteriostatic water for the 11.6 mg/vial formulation. This produces approximately 8.92 mg/mL by simple concentration calculation.

How much BAC water for Tesamorelin 2 mg?

The 2 mg EGRIFTA SV formulation is different. Its FDA labeling specifies Sterile Water for Injection rather than bacteriostatic water, with a labeled reconstitution volume of 0.5 mL. Therefore, information for the 11.6 mg EGRIFTA WR formulation should not be transferred to EGRIFTA SV.

How does BAC-water volume change Tesamorelin concentration?

Concentration is inversely related to liquid volume when the total compound quantity remains constant. Increasing the liquid volume produces a lower concentration; decreasing the liquid volume produces a higher concentration.

What Is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing factor (GHRF). It acts at growth hormone-releasing factor receptors and stimulates endogenous growth hormone release. The resulting endocrine pathway includes changes in insulin-like growth factor 1 (IGF-1).

Compound class

Tesamorelin is a GHRF analog designed to mimic the activity of endogenous growth hormone-releasing factor.

GHRF / GHRH analog
Peptide-based compound
Acts through the GH-releasing pathway
Associated with increased IGF-1 signaling

Regulatory distinction

Tesamorelin has FDA-licensed formulations for a specific indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.

The FDA labeling explicitly states that EGRIFTA products are not indicated for general weight-loss management.

How Tesamorelin Works

Tesamorelin activates growth hormone-releasing factor receptors. This increases endogenous growth hormone secretion, which can subsequently influence IGF-1 and body-composition pathways.

1. GHRF receptor signaling

Tesamorelin binds to and stimulates human growth hormone-releasing factor receptors. This is the initiating step in the endocrine pathway.

2. Growth hormone release

GHRF receptor activation stimulates the pituitary pathway responsible for endogenous growth hormone synthesis and pulsatile release.

3. IGF-1 response

FDA labeling notes that Tesamorelin stimulates growth hormone production and increases serum IGF-1.

4. Visceral adipose tissue

Randomized clinical trials in people with HIV-associated abdominal adiposity found reductions in visceral adipose tissue during Tesamorelin treatment.

What Is Tesamorelin Being Studied For?

The strongest human evidence concerns HIV-associated abdominal adiposity and visceral adipose tissue. Additional research has explored metabolic, hepatic, inflammatory and other potential applications.

VAT

Visceral adipose tissue

Multiple randomized trials reported reductions in visceral adipose tissue among HIV-infected adults with excess abdominal fat.

HIV-associated lipodystrophy

This is the clinical area in which Tesamorelin has the strongest regulatory and clinical evidence.

Metabolic and liver research

Clinical research has also evaluated liver fat and metabolic outcomes in selected HIV populations.

Human Clinical Research

Tesamorelin has been evaluated in randomized controlled trials, including large Phase 3 studies involving HIV-infected adults with excess abdominal fat.

Study	Population	Dose studied	Route	Frequency	Duration	Key finding
NEJM clinical trial	HIV-infected adults with abdominal fat accumulation	2 mg	Subcutaneous	Daily	26 weeks	Reduced visceral adipose tissue compared with placebo
Phase 3 pooled analysis	806 ART-treated HIV patients	2 mg	Subcutaneous	Daily	26 weeks + extension	Significant reduction in visceral adipose tissue
JAMA randomized trial	HIV-infected men and women with abdominal fat accumulation	2 mg	Subcutaneous	Daily	6 months	Reduced visceral adipose and liver fat

Research-dose clarification: The doses listed above are doses used in clinical research. They are not BacScience dosage recommendations and should not be interpreted as a personalized treatment plan.

Doses Studied in Published Research

Published clinical research commonly evaluated Tesamorelin at 2 mg administered subcutaneously once daily in HIV-associated abdominal adiposity studies. More recent FDA-approved formulations have different labeled dosage strengths and administration instructions.

Evidence source	Population	Reported dose	Duration	Primary research focus
Falutz et al.	HIV patients with excess abdominal fat	2 mg daily	26 weeks	Visceral adipose tissue
Falutz et al. extension	HIV patients with abdominal adiposity	2 mg daily	52 weeks	Long-term VAT response and safety
Stanley et al.	HIV-infected adults with abdominal fat accumulation	2 mg daily	6 months	VAT and liver fat

These research doses should not be confused with the formulation-specific instructions for EGRIFTA SV or EGRIFTA WR.

Preclinical Research

Tesamorelin's biological activity is based on stimulation of the growth hormone-releasing factor pathway. Preclinical and mechanistic research helps explain its endocrine effects, but preclinical findings should not be treated as evidence of clinical effectiveness in humans.

Human evidence vs. laboratory evidence

Human: randomized clinical trials have evaluated Tesamorelin in HIV-associated abdominal adiposity.
Mechanistic: receptor and endocrine studies describe GHRF receptor activation and downstream GH/IGF-1 signaling.
Preclinical: laboratory evidence can help establish biological mechanisms but cannot establish a human treatment dose.

Research Reconstitution & Concentration

Reconstitution changes a dry or lyophilized compound into a liquid preparation. From a purely mathematical perspective, concentration is determined by the amount of compound divided by the liquid volume.

Concentration (mg/mL) = Total Tesamorelin (mg) ÷ Liquid Volume (mL)

This equation calculates concentration. It does not determine whether a particular diluent, volume, route, dose, storage condition or preparation method is clinically appropriate.

11.6 mg ÷ 1 mL 11.6 mg/mL

11.6 mg ÷ 1.3 mL ≈ 8.92 mg/mL

11.6 mg ÷ 2 mL 5.8 mg/mL

BAC Water vs. Tesamorelin Concentration

BAC water is a diluent. Its volume changes the concentration of the compound in solution. It does not create additional Tesamorelin or change the total amount of compound represented by the vial.

More liquid

If the total Tesamorelin quantity remains constant, increasing liquid volume lowers the concentration.

Example: 11.6 mg ÷ 5 mL = 2.32 mg/mL

Less liquid

If the total Tesamorelin quantity remains constant, decreasing liquid volume raises the concentration.

Example: 11.6 mg ÷ 1 mL = 11.6 mg/mL

Important: Mathematical concentration does not tell you which concentration should be used clinically. Product labeling and qualified healthcare-professional instructions take precedence over generalized online calculations.

Research Limitations & Safety

Tesamorelin is not simply an unrestricted research peptide. FDA-licensed Tesamorelin formulations have specific indications, contraindications, warnings and formulation-specific preparation requirements.

FDA-approved indication

EGRIFTA formulations are indicated for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

FDA labeling states that the product is not indicated for general weight-loss management.

Important warnings

Potential increase in IGF-1.
Potential glucose intolerance or diabetes.
Fluid retention may occur.
Hypersensitivity reactions have occurred.
Active malignancy is a contraindication.
Pregnancy is a contraindication.

Formulation warning: EGRIFTA SV and EGRIFTA WR have different vial strengths, diluents, reconstitution requirements, dosage strengths and storage instructions. The FDA states that the formulations are not interchangeable.

Frequently Asked Questions About Tesamorelin BAC Water

How much BAC water is used with Tesamorelin?

There is no universal volume for every Tesamorelin formulation. FDA labeling for EGRIFTA WR specifies 1.3 mL of bacteriostatic water for an 11.6 mg vial. EGRIFTA SV is a different 2 mg formulation and specifies Sterile Water for Injection instead.

How much BAC water for 11.6 mg Tesamorelin?

For the FDA-approved EGRIFTA WR 11.6 mg/vial formulation, the FDA labeling specifies 1.3 mL of bacteriostatic water. The resulting mathematical concentration is approximately 8.92 mg/mL.

What is the concentration of 11.6 mg Tesamorelin in 1.3 mL?

11.6 mg divided by 1.3 mL equals approximately 8.92 mg/mL.

What is the concentration of 11.6 mg Tesamorelin in 1 mL?

Mathematically, 11.6 mg divided by 1 mL equals 11.6 mg/mL. This is a concentration calculation, not a recommendation to use 1 mL for a specific product.

Can EGRIFTA SV and EGRIFTA WR be treated as the same Tesamorelin formulation?

No. They have different strengths and formulation-specific preparation requirements. FDA labeling specifically distinguishes the formulations.

Does more BAC water make Tesamorelin weaker?

More liquid produces a lower mathematical concentration when the total compound quantity remains constant. It does not reduce the total amount of Tesamorelin contained in the vial.

How do you calculate Tesamorelin concentration?

Use the formula: Total Tesamorelin in mg divided by liquid volume in mL. For example, 11.6 mg divided by 1.3 mL equals approximately 8.92 mg/mL.

Is BAC water the same as Sterile Water for Injection?

No. They are different diluent products with different characteristics. The appropriate diluent depends on the specific pharmaceutical formulation and its labeling.

Is Tesamorelin FDA approved?

FDA-licensed Tesamorelin formulations exist. The FDA-approved indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. FDA labeling does not establish Tesamorelin as a general weight-loss treatment.

What dose of Tesamorelin has been studied in clinical trials?

Multiple clinical trials in HIV-associated abdominal adiposity studied 2 mg subcutaneously once daily. Research doses are presented here as historical study information and are not BacScience treatment recommendations.

Does BacScience recommend a Tesamorelin dose?

No. BacScience provides educational information and concentration mathematics. Clinical dosing decisions should follow the applicable product labeling and guidance from a qualified healthcare professional.

Can I use the BAC Water Calculator for a different Tesamorelin vial?

The calculator can perform the mathematical concentration calculation for a custom vial quantity and liquid volume. The resulting number should not be interpreted as a recommendation that the selected diluent or volume is appropriate for a particular pharmaceutical product.

Related BacScience Research Resources

Universal BAC Water Calculator

Calculate mathematical concentration from vial quantity and liquid volume.

Open Calculator

Research & Reconstitution Library

Explore compound-specific research, concentration mathematics and reconstitution education.

Explore Research Library

Peptide Research Library

Explore additional peptide research pages and compound-specific scientific resources.

Explore Peptide Research

BAC Water Resources

Learn about bacteriostatic water, concentration, formulation differences and scientific handling concepts.

Explore BAC Water Resources

Scientific References

U.S. Food and Drug Administration — EGRIFTA WR Prescribing Information. FDA labeling covering the 11.6 mg/vial formulation, bacteriostatic-water diluent and formulation-specific administration information.
View FDA EGRIFTA WR label
U.S. Food and Drug Administration — EGRIFTA SV Prescribing Information. FDA labeling covering the 2 mg/vial formulation and its Sterile Water for Injection diluent.
View FDA EGRIFTA SV label
Stanley TL et al. JAMA, 2014. Effect of Tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation.
View PubMed record
Falutz J et al. Journal of Clinical Endocrinology & Metabolism, 2010. Pooled Phase 3 analysis of Tesamorelin in HIV-infected patients with excess abdominal fat.
View PubMed record
Falutz J et al. AIDS / HIV Medicine research. Long-term safety and effects of Tesamorelin in HIV patients with abdominal fat accumulation.
View PubMed record
ClinicalTrials.gov. Tesamorelin clinical trial records and study registration data.
Search ClinicalTrials.gov

Last Scientifically Reviewed

Date: September 10, 2026

Scientific content basis: FDA prescribing information, FDA regulatory records, PubMed-indexed clinical research and ClinicalTrials.gov.

Content scope: Tesamorelin identity, regulatory status, formulation distinctions, published human research, concentration mathematics and educational BAC-water/reconstitution information.

Educational and research disclaimer: This page is provided for scientific education and research information. Mathematical concentration examples are not medical prescriptions and do not establish a recommended dose, injection volume, route, diluent, storage condition or treatment protocol. Product-specific preparation instructions should come from the applicable official labeling and qualified healthcare professionals. Do not substitute information from one Tesamorelin formulation for another.